Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536922 | 1.00 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8157337 | 1.00 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13848517 | 1.00 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL5109031 | 0.84 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL16488278 | 0.84 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13495829 | 0.84 | SRD5A1 (0.64) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL25247958 | 0.83 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4266160 | 0.83 | SRD5A1 (0.66) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL4266165 | 0.83 | SRD5A1 (0.66) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8536979 | 0.82 | SRD5A1 (0.52) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007010-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AZASTEROID | GLAXO GROUP LIMITED (GB) | 2000-06-14 | — | — | EP | claimed |
| EP-1005346-A2 | SOLUTIONS CONTAINING AZASTEROIDS | GLAXO GROUP LIMITED (GB) | 2000-06-07 | — | — | EP | claimed |
| WO-1999008684-A2 | SOLUTIONS CONTAINING AZASTEROIDS | GLAXO GROUP LIMITED (GB) | 1999-02-25 | — | — | WO | claimed |
| WO-1999008666-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AZATEROID | GLAXO GROUP LIMITED (GB) | 1999-02-25 | — | — | WO | claimed |
| JP-4288096-A | — | — | None | — | — | JP | disclosed |
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5760045-A | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5693809-A | PREGNANES FOR TREATING ALOPECIA, ACNE AND SKIN DISORDER | MERCK & CO., INC. (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0646007-B1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5510351-A | PREGNANE ENZYME INHIBITOR FOR TREATING SKIN DISORDER, BALDNESS, PROSTATIC CANCER | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| JP-H04288096-A | NEW PRODUCTION METHOD OF 3-OXO-4-AZA-ANDROST-1-ENE 17 BETA-KETONE | MERCK & CO INC | 1992-10-13 | — | — | JP | disclosed |
| EP-0478066-A2 | New process for making 3-oxo-4-aza-androst-1-ene 17beta-ketones | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478066-A2 | New process for making 3-oxo-4-aza-androst-1-ene 17beta-ketones | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478065-A2 | New intermediate for making 3-oxo-4-aza-androst-1-ene 17beta-ketones | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478065-A2 | New intermediate for making 3-oxo-4-aza-androst-1-ene 17beta-ketones | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0462661-A2 | Novel 17beta-hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones as testosterone reductase inhibitors | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-5061801-A | Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones | MERCK & CO., INC. (US) | 1991-10-29 | — | — | US | disclosed |
| US-5061801-A | Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones | MERCK & CO., INC. (US) | 1991-10-29 | — | — | US | disclosed |